EP3703781B1 - Steuerung einer medizinischen vorrichtung mithilfe drahtloser kommunikation - Google Patents

Steuerung einer medizinischen vorrichtung mithilfe drahtloser kommunikation Download PDF

Info

Publication number
EP3703781B1
EP3703781B1 EP18792406.3A EP18792406A EP3703781B1 EP 3703781 B1 EP3703781 B1 EP 3703781B1 EP 18792406 A EP18792406 A EP 18792406A EP 3703781 B1 EP3703781 B1 EP 3703781B1
Authority
EP
European Patent Office
Prior art keywords
state
medicament
pen
dose
communication means
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18792406.3A
Other languages
English (en)
French (fr)
Other versions
EP3703781A1 (de
Inventor
Christian Peter Enggaard
Rune RAVN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP3703781A1 publication Critical patent/EP3703781A1/de
Application granted granted Critical
Publication of EP3703781B1 publication Critical patent/EP3703781B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A61M5/31545—Setting modes for dosing
    • A61M5/31546—Electrically operated dose setting, e.g. input via touch screen or plus/minus buttons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159—Dose expelling manners
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M2005/3125—Details specific display means, e.g. to indicate dose setting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/18—General characteristics of the apparatus with alarm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/27—General characteristics of the apparatus preventing use
    • A61M2205/276—General characteristics of the apparatus preventing use preventing unwanted use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3546—Range
    • A61M2205/3553—Range remote, e.g. between patient's home and doctor's office
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3546—Range
    • A61M2205/3561—Range local, e.g. within room or hospital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3546—Range
    • A61M2205/3569—Range sublocal, e.g. between console and disposable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/35—Communication
    • A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
    • A61M2205/3584—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or Bluetooth®
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/60—General characteristics of the apparatus with identification means
    • A61M2205/6009—General characteristics of the apparatus with identification means for matching patient with his treatment, e.g. to improve transfusion security
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31566—Means improving security or handling thereof
    • A61M5/31571—Means preventing accidental administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31566—Means improving security or handling thereof
    • A61M5/31573—Accuracy improving means

Definitions

  • Some diseases entail a treatment regimen that involves administration of more than one type of medicament. For example, many people suffering from diabetes need to administer different types of insulin at different times of day in order to control their blood sugar level. A person with diabetes may administer a long-acting insulin once or twice a day and in addition thereto a short-acting insulin before meal-times and whenever necessary to avoid long-term hyperglycaemia.
  • the software application program which may be stored in a memory of a data processor in the mobile communication unit or associated with a communication network accessible via the Internet and wirelessly linked with the mobile communication unit, may be configured to determine the recommended type of medicament to be delivered based at least in part on information sent from the pen communication means to the mobile communication means.
  • the software application program may further be configured to determine the recommended type of medicament to be delivered based on information about a current and/or trending glucose level of the user. Such information may be retrieved from a glucose monitoring device.
  • Prompting a change of state of the indication means from the second state to the first state may alternatively, or additionally, comprise disabling the dose expelling mechanism.
  • This could e.g. be realised by use of a solenoid arrangement similarly to the above described arrangement for disabling the dose setting mechanism, only where the pawl is displaceable to engage with the dose expelling mechanism, e.g. a piston actuator member.
  • the mobile communication means may e.g. be adapted to communicate with the pen injection device via Bluetooth or near field communication (NFC) protocols and the mobile communication unit may thus be able to affect the indication means as long as the pen injection device is within the communication radius of the mobile communication unit.
  • NFC near field communication
  • system may be configured to prevent operation of the pen injection device, e.g. to prevent dose setting and/or dose expelling, if the pen injection device is outside the communication radius of the mobile communication unit.
  • a dosing system of two pen injection devices carrying different types of drug e.g. long acting insulin, respectively rapid acting insulin
  • different types of drug e.g. long acting insulin, respectively rapid acting insulin
  • the mobile communication unit may be controlled by the mobile communication unit to clearly indicate to the user which of them is to be used for an impending injection, eliminating, or at least markedly reducing, the risk of the user inadvertently injecting the type of drug which is not presently recommended.
  • a system which signals to the user that she is expelling a type of medicament which differs from a recommended type of medicament, allowing her to either carry on with the knowledge that a different type of medicament is being administered or to interrupt the dose expelling and perform any remedial actions.
  • Fig. 1 shows a system 1 according to an exemplary embodiment of the invention.
  • the system 1 comprises a first injection pen 10 holding a first medicament, "Drug A”, a second injection pen 20 holding a second medicament, "Drug B", and a smartphone 30 adapted for bidirectional communication with each of the two injection pens 10, 20.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • General Business, Economics & Management (AREA)
  • Business, Economics & Management (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Claims (12)

  1. System (1), umfassend:
    - eine erste Pen-Injektionsvorrichtung (10), die einen ersten spezifischen Medikamententyp enthält und einen ersten Dosisausstoßmechanismus, erste Pen-Kommunikationsmittel (15) und erste Anzeigemittel umfasst, die in einem ersten Zustand anzeigen, dass der erste Dosisausstoßmechanismus inaktiv bleiben soll, und in einem zweiten Zustand anzeigen, dass der erste Dosisausstoßmechanismus für den Betrieb verfügbar ist,
    - eine zweite Pen-Injektionsvorrichtung (20), die einen zweiten spezifischen Medikamententyp enthält und einen zweiten Dosisausstoßmechanismus, zweite Pen-Kommunikationsmittel (25) und zweite Anzeigemittel umfasst, die in einem ersten Zustand anzeigen, dass der zweite Dosisausstoßmechanismus inaktiv bleiben soll, und in einem zweiten Zustand anzeigen, dass der zweite Dosisausstoßmechanismus für den Betrieb verfügbar ist,
    - eine mobile Kommunikationseinheit (30), die mobile Kommunikationsmittel (35) umfasst, die zum Kommunizieren mit den ersten Pen-Kommunikationsmitteln (15) und den zweiten Pen-Kommunikationsmitteln (25) ausgelegt ist, und
    - ein Software-Anwendungsprogramm, das konfiguriert ist, einen empfohlenen Medikamententyp, der an einen Benutzer abgegeben werden soll, als einen von dem ersten spezifischen Medikamententyp und dem zweiten spezifischen Medikamententyp basierend auf Informationen, die einen physiologischen Zustand des Benutzers anzeigen, zu bestimmen,
    wobei die mobile Kommunikationseinheit (30) konfiguriert ist, über eine Kommunikation von den mobilen Kommunikationsmitteln (35) an zumindest eines von den ersten Pen-Kommunikationsmitteln (15) und den zweiten Pen-Kommunikationsmitteln (25),
    - eine Zustandsänderung der ersten Anzeigemittel von dem zweiten Zustand in den ersten Zustand und/oder eine Zustandsänderung der zweiten Anzeigemittel von dem ersten Zustand in den zweiten Zustand in Reaktion darauf, dass der empfohlene abzugebende Medikamententyp der zweite spezifische Medikamententyp ist, zu veranlassen, und
    - eine Zustandsänderung der zweiten Anzeigemittel von dem zweiten Zustand in den ersten Zustand und/oder eine Zustandsänderung der ersten Anzeigemittel von dem ersten Zustand in den zweiten Zustand in Reaktion darauf, dass der empfohlene abzugebende Medikamententyp der erste spezifische Medikamententyp ist, zu veranlassen.
  2. System nach Anspruch 1, wobei das Software-Anwendungsprogramm konfiguriert ist, den empfohlenen abzugebenden Medikamententyp zumindest teilweise basierend auf Informationen zu bestimmen, die von den ersten Pen-Kommunikationsmitteln (15) an die mobilen Kommunikationsmittel (35) gesendet werden.
  3. System nach Anspruch 1 oder 2, wobei die erste Pen-Injektionsvorrichtung (10) ferner einen Dosiseinstellmechanismus umfasst, der zum Einstellen einer abzugebenden Dosis verwendet werden kann.
  4. System nach Anspruch 3, wobei das Veranlassen einer Zustandsänderung der ersten Anzeigemittel von dem zweiten Zustand in den ersten Zustand das Deaktivieren des Dosiseinstellmechanismus umfasst.
  5. System nach Anspruch 3 oder 4, wobei die erste Pen-Injektionsvorrichtung (10) ferner eine Dosisanzeige (12) zur visuellen Bestätigung einer eingestellten Dosis umfasst, und wobei das Veranlassen einer Zustandsänderung der ersten Anzeigemittel von dem zweiten Zustand in den ersten Zustand das Beeinflussen der Dosisanzeige (12) umfasst.
  6. System nach einem der vorhergehenden Ansprüche, wobei die erste Pen-Injektionsvorrichtung (10) ferner einen Tongenerator umfasst, und wobei das Veranlassen einer Zustandsänderung der ersten Anzeigemittel von dem zweiten Zustand in den ersten Zustand das Erzeugen eines Benachrichtigungstons über den Tongenerator umfasst.
  7. System nach einem der vorhergehenden Ansprüche, wobei das Veranlassen einer Zustandsänderung der ersten Anzeigemittel von dem zweiten Zustand in den ersten Zustand das Deaktivieren des ersten Dosisausstoßmechanismus umfasst.
  8. System nach einem der Ansprüche 1 bis 6, wobei die mobile Kommunikationseinheit (30) ferner einen Alarmgenerator umfasst, der zur Ausgabe eines Alarmsignals ausgelegt ist, wobei die ersten Pen-Kommunikationsmittel (15) konfiguriert sind, einen laufenden Betrieb des ersten Dosisausstoßmechanismus zu registrieren und den mobilen Kommunikationsmitteln (35) mitzuteilen, und wobei der Alarmgenerator konfiguriert ist, das Alarmsignal auszugeben, wenn die mobilen Kommunikationsmittel (35) eine Benachrichtigung von den ersten Pen-Kommunikationsmitteln (15) empfangen und der empfohlene Medikamententyp der zweite spezifische Medikamententyp ist.
  9. System nach einem der Ansprüche 3 bis 5, wobei die mobile Kommunikationseinheit (30) ferner einen Alarmgenerator umfasst, der zur Ausgabe eines Alarmsignals ausgelegt ist, wobei die ersten Pen-Kommunikationsmittel (15) konfiguriert sind, einen laufenden Betrieb des ersten Dosiseinstellmechanismus zu registrieren und den mobilen Kommunikationsmitteln (35) mitzuteilen, und wobei der Alarmgenerator konfiguriert ist, das Alarmsignal auszugeben, wenn die mobilen Kommunikationsmittel (35) eine Benachrichtigung von den ersten Pen-Kommunikationsmitteln (15) empfangen und der empfohlene Medikamententyp der zweite spezifische Medikamententyp ist.
  10. System nach einem der vorhergehenden Ansprüche, wobei der empfohlene Medikamententyp aus einer Gruppe ausgewählt wird, die aus a) einem ersten Typ eines Diabetes-Medikaments und b) einem zweiten Typ eines Diabetes-Medikaments besteht.
  11. System nach Anspruch 10, wobei der erste Typ des Diabetes-Medikaments ein schnell wirkendes Insulin ist und der zweite Typ des Diabetes-Medikaments ein lang wirkendes Insulin ist.
  12. System nach Anspruch 1, wobei das Veranlassen einer Zustandsänderung der ersten Anzeigemittel von dem ersten Zustand in den zweiten Zustand das Bereitstellen eines optischen, akustischen und/oder taktilen Signals umfasst, dass die erste Pen-Injektionsvorrichtung (10) zum Gebrauch bereit ist.
EP18792406.3A 2017-10-31 2018-10-31 Steuerung einer medizinischen vorrichtung mithilfe drahtloser kommunikation Active EP3703781B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17199399 2017-10-31
PCT/EP2018/079847 WO2019086527A1 (en) 2017-10-31 2018-10-31 Control of medical device using wireless communication

Publications (2)

Publication Number Publication Date
EP3703781A1 EP3703781A1 (de) 2020-09-09
EP3703781B1 true EP3703781B1 (de) 2021-12-08

Family

ID=60201443

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18792406.3A Active EP3703781B1 (de) 2017-10-31 2018-10-31 Steuerung einer medizinischen vorrichtung mithilfe drahtloser kommunikation

Country Status (5)

Country Link
US (1) US12224050B2 (de)
EP (1) EP3703781B1 (de)
JP (1) JP7235745B2 (de)
CN (1) CN111263650B (de)
WO (1) WO2019086527A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114786748B (zh) * 2019-12-12 2025-10-24 赛诺菲 包括考虑环境信号的警报生成器的医疗装置
US20250032724A1 (en) * 2021-11-03 2025-01-30 Sanofi Injection device and method of unlocking operation of the injection device
CN118234527A (zh) * 2021-11-03 2024-06-21 赛诺菲 注射装置及注射装置的解锁操作方法
EP4426393A1 (de) * 2021-11-03 2024-09-11 Sanofi Injektionsvorrichtung und verfahren zum entriegeln des betriebs der injektionsvorrichtung

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010492A (en) 1997-02-07 2000-01-04 Sarcos, Lc Apparatus for automatic administration of multiple doses of drugs
US8251904B2 (en) * 2005-06-09 2012-08-28 Roche Diagnostics Operations, Inc. Device and method for insulin dosing
JP4943728B2 (ja) * 2006-03-30 2012-05-30 テルモ株式会社 血糖計
US8221345B2 (en) * 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
JP2012507309A (ja) 2008-07-18 2012-03-29 ライフスキャン・インコーポレイテッド 分析物測定及び管理装置並びに関連した方法
JP5711155B2 (ja) * 2009-02-27 2015-04-30 ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． 薬物送達ペンのための医療モジュール
US20100286612A1 (en) * 2009-05-06 2010-11-11 William Cirillo Medication injection supervisor device
TW201808357A (zh) 2010-03-22 2018-03-16 賽諾菲阿凡提斯德意志有限公司 用於判定與醫療裝置有關的資訊之裝置、方法、系統及電腦程式
EP2572740A1 (de) 2011-09-20 2013-03-27 Roche Diagnostics GmbH Arzneimittelinjektionsvorrichtungen und Systeme mit einer Analytenmessung
US20140324020A1 (en) 2011-10-11 2014-10-30 Novo Nordisk A/S Dual Purpose Advisory Device
WO2014152704A1 (en) 2013-03-15 2014-09-25 Becton, Dickinson And Company Smart adapter for infusion devices
EP3049132B1 (de) * 2013-09-26 2020-08-19 Companion Medical, Inc. Medikamentenabgabesystem
GB201407896D0 (en) 2014-05-05 2014-06-18 Joanneum Res Forschungsgmbh Insulin dosage proposal system
CN112237662B (zh) 2014-06-03 2022-10-21 安姆根有限公司 药物递送系统和使用方法
WO2016007935A2 (en) * 2014-07-10 2016-01-14 Companion Medical, Inc. Medicine administering system including injection pen and companion device
US10252002B2 (en) 2014-08-01 2019-04-09 Becton, Dickinson And Company Continuous glucose monitoring injection device
JP2017529918A (ja) 2014-09-08 2017-10-12 メダクソール プロプライエタリー リミテッドＭｅｄａｘｏｒ Ｐｔｙ Ｌｔｄ 注射システム
US20170338864A1 (en) 2015-01-08 2017-11-23 Novo Nordisk A/S A Wireless Data Communication Module for Drug Injection Devices
EP3042676A1 (de) 2015-01-12 2016-07-13 Sanofi-Aventis Deutschland GmbH Zusatzmodul für stiftartigen arzneimittelinjektor zur bestimmung der eingestellten dosis via optischer zeichenerkennung (ocr)
EP3250263B1 (de) * 2015-01-27 2022-04-27 SHL Medical AG Medikamentenverabreichungsvorrichtung

Also Published As

Publication number Publication date
JP2021501000A (ja) 2021-01-14
EP3703781A1 (de) 2020-09-09
CN111263650A (zh) 2020-06-09
US12224050B2 (en) 2025-02-11
WO2019086527A1 (en) 2019-05-09
CN111263650B (zh) 2022-06-21
US20200294646A1 (en) 2020-09-17
JP7235745B2 (ja) 2023-03-08

Similar Documents

Publication Publication Date Title
US11826555B2 (en) Automatic medication delivery tracking
US11116900B2 (en) Continuous glucose monitoring injection device
US11383043B2 (en) Medicine injection and disease management systems, devices, and methods
CN106413781B (zh) 由药物输送设备操作的记录设备
US11197963B2 (en) Device for attachment to an injection device
CN101627386B (zh) 有时间变化特征的日志功能的显示信息的设备和方法
CA2925458C (en) System for administering a medicament
US12224050B2 (en) Control of medical device using wireless communication
US20160259913A1 (en) Drug delivery dose indicator
US20090212966A1 (en) User Interface for Delivery System Providing Dual Setting of Parameters
CN101238464A (zh) 提供快捷导航的输送系统用户接口
CN101541360A (zh) 包括日志功能的输送系统用户界面
CN105324142A (zh) 用于附接到注射装置的补充装置
US12592307B2 (en) Computerized system and method for the determination of a drug dosage, and computer program
KR101644995B1 (ko) 당뇨환자 관리 시스템 및 방법
CN118159315A (zh) 带有改善的使用体验的给予装置

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210528

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1453273

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211215

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018027941

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20211208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220308

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1453273

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220308

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220408

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018027941

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220408

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

26N No opposition filed

Effective date: 20220909

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20221031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211208

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250923

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250924

Year of fee payment: 8

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250923

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251101

Year of fee payment: 8